Increased ErbB2 Signaling Is an Early Adaptation to Androgen Signaling Inhibition and Persists in Castration-Resistant Prostate Cancer.

ABSTRACT:

Purpose

ErbB2 activity is increased in a subset of prostate cancer, but the gene is rarely amplified. This study sought to identify mechanisms driving increased ErbB2 activity and their role in progression to castration-resistant prostate cancer (CRPC).

Experimental design

ErbB2 signaling was interrogated with a combination of immunohistochemistry, reverse-phase protein array, and RNA sequencing in cell lines, xenografts, and clinical tumors at various stages of castration resistance. Sensitivity to ErbB2 inhibitors was tested in vitro and in vivo.

Results

ErbB2 activation, identified by IHC with an antibody against phosphorylated ErbB2, was present in ∼26% of residual tumors in radical prostatectomies after neoadjuvant androgen signaling inhibition (ASI) and in advan

SUBMITTER: Owiredu J 

PROVIDER: S-EPMC12580767 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature